Rifaximin Treatment in Hepatic Encephalopathy
| Autor: | Kunal Merchant, Muhammad Y. Sheikh, Carroll B. Leevy, Nathan M. Bass, Fred Poordad, Kimberly Beavers, Donald J. Hillebrand, Lewis W. Teperman, Kevin D. Mullen, William P. Forbes, Shirley Huang, Guy W. Neff, Arun J. Sanyal, Samuel H. Sigal, Audrey L. Shaw, Enoch Bortey, Todd Frederick |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Liver Cirrhosis
Male medicine.medical_specialty Cirrhosis Encephalopathy Kaplan-Meier Estimate Placebo Gastroenterology Rifaximin chemistry.chemical_compound Lactulose Anti-Infective Agents Double-Blind Method Gastrointestinal Agents Internal medicine Secondary Prevention medicine Humans Hepatic encephalopathy Aged Proportional Hazards Models Antibacterial agent Gastrointestinal agent Clostridioides difficile business.industry General Medicine Middle Aged medicine.disease Rifamycins Intention to Treat Analysis Surgery Hospitalization chemistry Hepatic Encephalopathy Chronic Disease Clostridium Infections Drug Therapy Combination Female business medicine.drug |
| Zdroj: | New England Journal of Medicine. 362:1071-1081 |
| ISSN: | 1533-4406 0028-4793 |
| Popis: | Background Hepatic encephalopathy is a chronically debilitating complication of hepatic cirrhosis. The efficacy of rifaximin, a minimally absorbed antibiotic, is well documented in the treatment of acute hepatic encephalopathy, but its efficacy for prevention of the disease has not been established. Methods In this randomized, double-blind, placebo-controlled trial, we randomly assigned 299 patients who were in remission from recurrent hepatic encephalopathy resulting from chronic liver disease to receive either rifaximin, at a dose of 550 mg twice daily (140 patients), or placebo (159 patients) for 6 months. The primary efficacy end point was the time to the first breakthrough episode of hepatic encephalopathy. The key secondary end point was the time to the first hospitalization involving hepatic encephalopathy. Results Rifaximin significantly reduced the risk of an episode of hepatic encephalopathy, as compared with placebo, over a 6-month period (hazard ratio with rifaximin, 0.42; 95% confidence interval [CI], 0.28 to 0.64; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|